95 related articles for article (PubMed ID: 17012877)
21. Cyclic AMP-Elevating Capacity of Adenylate Cyclase Toxin-Hemolysin Is Sufficient for Lung Infection but Not for Full Virulence of Bordetella pertussis.
Skopova K; Tomalova B; Kanchev I; Rossmann P; Svedova M; Adkins I; Bibova I; Tomala J; Masin J; Guiso N; Osicka R; Sedlacek R; Kovar M; Sebo P
Infect Immun; 2017 Jun; 85(6):. PubMed ID: 28396322
[TBL] [Abstract][Full Text] [Related]
22. Pore-forming and enzymatic activities of Bordetella pertussis adenylate cyclase toxin synergize in promoting lysis of monocytes.
Basler M; Masin J; Osicka R; Sebo P
Infect Immun; 2006 Apr; 74(4):2207-14. PubMed ID: 16552051
[TBL] [Abstract][Full Text] [Related]
23. Structure-function studies of the adenylate cyclase toxin of Bordetella pertussis and the leukotoxin of Pasteurella haemolytica by heterologous C protein activation and construction of hybrid proteins.
Westrop G; Hormozi K; da Costa N; Parton R; Coote J
J Bacteriol; 1997 Feb; 179(3):871-9. PubMed ID: 9006045
[TBL] [Abstract][Full Text] [Related]
24. [Influence of pertussis preparations on primary culture of peritoneal macrophages and continuous human monocyte-like cell line U937].
Tiukavkina SIu; Savis'ko AA; Kharseeva GG
Zh Mikrobiol Epidemiol Immunobiol; 2011; (2):85-7. PubMed ID: 21604390
[TBL] [Abstract][Full Text] [Related]
25. Outer membrane vesicles obtained from Bordetella pertussis Tohama expressing the lipid A deacylase PagL as a novel acellular vaccine candidate.
Asensio CJ; Gaillard ME; Moreno G; Bottero D; Zurita E; Rumbo M; van der Ley P; van der Ark A; Hozbor D
Vaccine; 2011 Feb; 29(8):1649-56. PubMed ID: 21211579
[TBL] [Abstract][Full Text] [Related]
26. Charge-dependent translocation of Bordetella pertussis adenylate cyclase toxin into eukaryotic cells: implication for the in vivo delivery of CD8(+) T cell epitopes into antigen-presenting cells.
Karimova G; Fayolle C; Gmira S; Ullmann A; Leclerc C; Ladant D
Proc Natl Acad Sci U S A; 1998 Oct; 95(21):12532-7. PubMed ID: 9770520
[TBL] [Abstract][Full Text] [Related]
27. Anti-viral protection conferred by recombinant adenylate cyclase toxins from Bordetella pertussis carrying a CD8+ T cell epitope from lymphocytic choriomeningitis virus.
Saron MF; Fayolle C; Sebo P; Ladant D; Ullmann A; Leclerc C
Proc Natl Acad Sci U S A; 1997 Apr; 94(7):3314-9. PubMed ID: 9096390
[TBL] [Abstract][Full Text] [Related]
28. An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis.
Majlessi L; Simsova M; Jarvis Z; Brodin P; Rojas MJ; Bauche C; Nouzé C; Ladant D; Cole ST; Sebo P; Leclerc C
Infect Immun; 2006 Apr; 74(4):2128-37. PubMed ID: 16552042
[TBL] [Abstract][Full Text] [Related]
29. Bordetella adenylate cyclase toxin: a unique combination of a pore-forming moiety with a cell-invading adenylate cyclase enzyme.
Masin J; Osicka R; Bumba L; Sebo P
Pathog Dis; 2015 Nov; 73(8):ftv075. PubMed ID: 26391732
[TBL] [Abstract][Full Text] [Related]
30. Antibodies to Bordetella pertussis adenylate cyclase toxin in neonatal and maternal sera.
Arciniega JL; Hewlett EL; Edwards KM; Burns DL
FEMS Immunol Med Microbiol; 1993 Apr; 6(4):325-30. PubMed ID: 8499896
[TBL] [Abstract][Full Text] [Related]
31. Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein.
Préville X; Ladant D; Timmerman B; Leclerc C
Cancer Res; 2005 Jan; 65(2):641-9. PubMed ID: 15695409
[TBL] [Abstract][Full Text] [Related]
32. [Cellular and acellular anti-pertussis vaccines].
Locht C
Ann Pharm Fr; 2001 May; 59(3):198-205. PubMed ID: 11427821
[TBL] [Abstract][Full Text] [Related]
33. Assay of pertussis vaccine reactivity factors by measurement of the paw swelling response, endotoxin and histamine-sensitizing factor.
Vuolo AM; Lustigman B
Biologicals; 1993 Mar; 21(1):45-52. PubMed ID: 8217117
[TBL] [Abstract][Full Text] [Related]
34. Genetically detoxified pertussis toxin (PT-9K/129G): implications for immunization and vaccines.
Seubert A; D'Oro U; Scarselli M; Pizza M
Expert Rev Vaccines; 2014 Oct; 13(10):1191-204. PubMed ID: 25183193
[TBL] [Abstract][Full Text] [Related]
35. Pore-formation by adenylate cyclase toxoid activates dendritic cells to prime CD8+ and CD4+ T cells.
Svedova M; Masin J; Fiser R; Cerny O; Tomala J; Freudenberg M; Tuckova L; Kovar M; Dadaglio G; Adkins I; Sebo P
Immunol Cell Biol; 2016 Apr; 94(4):322-33. PubMed ID: 26437769
[TBL] [Abstract][Full Text] [Related]
36. Bordetella pertussis adenylate cyclase toxin and hemolytic activities require a second gene, cyaC, for activation.
Barry EM; Weiss AA; Ehrmann IE; Gray MC; Hewlett EL; Goodwin MS
J Bacteriol; 1991 Jan; 173(2):720-6. PubMed ID: 1987161
[TBL] [Abstract][Full Text] [Related]
37. Human serum antibody responses to Bordetella pertussis infection and pertussis vaccination.
Thomas MG; Redhead K; Lambert HP
J Infect Dis; 1989 Feb; 159(2):211-8. PubMed ID: 2536779
[TBL] [Abstract][Full Text] [Related]
38. Inflammasome activation by adenylate cyclase toxin directs Th17 responses and protection against Bordetella pertussis.
Dunne A; Ross PJ; Pospisilova E; Masin J; Meaney A; Sutton CE; Iwakura Y; Tschopp J; Sebo P; Mills KH
J Immunol; 2010 Aug; 185(3):1711-9. PubMed ID: 20610650
[TBL] [Abstract][Full Text] [Related]
39. Antibody responses in adult and neonatal BALB/c mice to immunization with novel Bordetella pertussis vaccine formulations.
Gracia A; Polewicz M; Halperin SA; Hancock RE; Potter AA; Babiuk LA; Gerdts V
Vaccine; 2011 Feb; 29(8):1595-604. PubMed ID: 21215343
[TBL] [Abstract][Full Text] [Related]
40. Examination of similarities between diphtheria and pertussis and their toxoids provide insight into vaccine-induced protection to Bordetella pertussis.
Schneerson R; Robbins JB; Taranger J; Lagerård T; Trollfors B
Dev Biol Stand; 1997; 89():321-6. PubMed ID: 9272366
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
